Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Feb. 27, 2012 - PRLog -- GlobalData estimates that the global myelofibrosis therapeutics market was worth $111.1m in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 16.9% to $1,133.4m by 2019. The current treatment options for myelofibrosis offer only symptomatic relief and primarily comprise off-label drugs. There are no disease-modifying myelofibrosis drugs, and the drugs in the late stage pipeline also only relieve symptoms, although they have good efficacy and safety profiles. The US Food and Drug
Administration (FDA) approved Jakafi in November 2011, which is so far the only approved product for myelofibrosis. As a result, the myelofibrosis market is expected to see significant growth during the forecast period.

The current treatment options for myelofibrosis are limited. Symptomatic treatment with simple corticosteroids, androgens, immunomodulatory drugs and cytotoxic agents is used but only to relieve the associated symptoms, such as anemia, splenomegaly, fever and sweating during sleep.

The current market lacks disease modifying drugs and consequently the significant unmet need is expected to continue throughout the forecast period. There are no disease-modifying drugs in the late stage of the pipeline, increasing patient reliance on purely symptomatic relief.

The myelofibrosis market is underserved by the currently marketed drugs as none provide a cure for the disease. As result, there is huge potential for new entrants with drugs that halt or reverse disease progression while simultaneously offering good efficacy and safety profiles. There is also huge potential for novel therapies which offer better symptomatic relief. A convenient route of administration and schedule, enhanced long term efficacy and safety profile and cost effectiveness will also prove advantageous

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages....


GlobalData, the industry analysis specialist, has released its new report, “Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global myelofibrosis market. The report identifies the key trends shaping and driving the global myelofibrosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global myelofibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Myel...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.